Chargement en cours...
EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2005
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC549608/ https://ncbi.nlm.nih.gov/pubmed/15736989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.0020075 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|